Patient registries are emerging as critical tools in hidradenitis suppurativa (HS) care, aggregating clinical, genetic, and lifestyle data to address the condition’s variability and support research. By centralizing information from scattered cases, these registries accelerate drug development, optimize trial design, and improve personalized care—ultimately shaping the HS market’s trajectory.

The HS Global Registry (HSGR), managed by the International HS Society, now includes over 10,000 patient records (2026 update), up from 6,000 in 2021. These data reveal patterns in disease progression: patients with obesity and smoking history experience 2x more severe flare-ups, guiding prevention strategies. HSGR also tracks treatment responses, showing that biologics reduce recurrence by 50% in advanced HS cases. To explore how registries influence market strategies, the HS Patient Registries section in Market Research Future’s report analyzes data sharing partnerships and R&D efficiency gains.

Registries streamline trial recruitment. A 2023 Phase III trial for an IL-23 inhibitor used HSGR data to identify eligible patients across 20 countries, cutting enrollment time by 40%. This efficiency reduces development costs by an estimated $5 million per trial (Market Research Future). Additionally, registries support patient advocacy by connecting families with clinical trials and educational resources. The Global HS Alliance noted that registry participation increases trial enrollment rates by 30% among underrepresented groups.

Market Research Future predicts that registries will enable a 35% reduction in HS drug development timelines by 2027. As data standardization improves, firms are investing in partnerships with registry managers. For example, a 2026 collaboration between a biotech and HSGR links genetic data with treatment outcomes, informing next-generation therapies. Patient registries thus serve as both a research backbone and a market growth catalyst, ensuring innovation aligns with patient needs.